Skip to content

To evaluate the improvement of quality of life and adverse reactions in patients with gastric cancer treated with Wushen holographic nutritional food combined with chemotherapy

To evaluate the improvement of quality of life and adverse reactions in patients with gastric cancer treated with Wushen holographic nutritional food combined with chemotherapy

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000031300
Enrollment
Unknown
Registered
2020-03-27
Start date
2018-12-18
Completion date
Unknown
Last updated
2020-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

stomach cancer

Interventions

Group 1:Chemotherapy treatment method + Wushen holographic nutrition food simulation agent
Group 2:Chemotherapy treatment + Wushen holographic nutrition food

Sponsors

Beijing Shijitan Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18 to 75 years; 2. Signed the informed consent; 3. gastric Cancer patient recurrence six months after neoadjuvant/adjuvant therapy.

Exclusion criteria

Exclusion criteria: 1. allergy to the contents of Wushen holographic nutritional food;

Design outcomes

Primary

MeasureTime frame
Quality of life (eortcqlq-c30);Adverse events;

Secondary

MeasureTime frame
Change of malnutrition status (pg-sga) and improvement of nutritional indicators (serum albumin, pre-albumin, transferrin, hemoglobin);Muscle strength indicators: grip strength changes;Tumor treatment status (c-reactive protein decline at the end of each cycle);Changes of immune cells from baseline (total number of lymphocytes and subtypes, neutrophil/lymphocyte ratio, IgG, IgM);Progression-free survival (PFS) and remission rate ORR (evaluated every 6 weeks) of subjects with the same treatment regimen after consuming the product;Objective remission of tumor (according to RECIST standard);

Countries

China

Contacts

Public ContactHangping Shi

Beijing Shijitan Hospital Affiliated to Capital Medical University

shihp@vip163.com+86 13802741263

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026